Kangzhong Biotechnology

Suzhou Kangzhong Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the development of innovative recombinant vaccines and therapeutic antibodies. The company utilizes its proprietary protein engineering and adjuvant technology platforms to create next-generation biologics targeting infectious diseases and oncology. Its most advanced program is a recombinant shingles vaccine designed to provide a high-efficacy alternative to existing global products. Additionally, Kangzhong is advancing a multi-valent HPV vaccine and several monoclonal antibody candidates through various stages of clinical and preclinical development. With integrated R&D and GMP-compliant manufacturing facilities, the company is positioned to address significant public health challenges in the Asian market and beyond.